Figure 3: STRO-001 showed potent cell killing activity on proliferating primary human B cells.

Oncotarget | Targeting CD74 in B-cell Non-Hodgkin Lymphoma With Antibody-Drug Conjugate STRO-001

“Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].”  Listen to an audio version of this press… read more